[HTML][HTML] A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic …
D Sohal, S Krishnamurthi, R Tohme, X Gu… - American journal of …, 2020 - ncbi.nlm.nih.gov
Abstract DNA methyltransferase 1 (DNMT1) is scientifically validated as a molecular target to
treat chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies …
treat chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies …
A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.
D Sohal, S Krishnamurthi, R Tohme, X Gu… - American Journal of …, 2020 - europepmc.org
Abstract DNA methyltransferase 1 (DNMT1) is scientifically validated as a molecular target to
treat chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies …
treat chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies …
A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer
D Sohal, S Krishnamurthi, R Tohme… - … journal of cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
DNA methyltransferase 1 (DNMT1) is scientifically validated as a molecular target to treat
chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies of the …
chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies of the …
[PDF][PDF] A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic …
D Sohal, S Krishnamurthi, R Tohme, X Gu, D Lindner… - e-century.us
DNA methyltransferase 1 (DNMT1) is scientifically validated as a molecular target to treat
chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies of the …
chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies of the …
[PDF][PDF] A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic …
D Sohal, S Krishnamurthi, R Tohme, X Gu, D Lindner… - academia.edu
DNA methyltransferase 1 (DNMT1) is scientifically validated as a molecular target to treat
chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies of the …
chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies of the …
A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer
D Sohal, S Krishnamurthi, R Tohme, X Gu, D Lindner… - 2020 - repository.arizona.edu
DNA methyltransferase 1 (DNMT1) is scientifically validated as a molecular target to treat
chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies of the …
chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies of the …